Edgewise says Phase 2 CIRRUS-HCM trial shows positive top-line data for EDG-7500 in hypertrophic cardiomyopathy

Reuters2026/08/24 12:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Edgewise Therapeutics flagged positive top-line results from its 12-week Phase 2 CIRRUS-HCM trial of EDG-7500 in symptomatic HCM.
Data have not yet been presented; the company scheduled a late-breaking presentation at the ESC Congress on Aug. 31, 2026.
Trial readout supported EDG-7500’s safety profile and showed efficacy signals in both obstructive and nonobstructive disease.
EDG-7500 is an oral cardiac sarcomere modulator aimed at improving relaxation while preserving systolic function, positioning it as a potential new HCM therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edgewise Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608240800PR_NEWS_USPR_____LA31716) on August 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Edgewise says Phase 2 CIRRUS-HCM trial shows positive top-line data for EDG-7500 in hypertrophic cardiomyopathy

You may also like

Crypto prices